BRAF and neoplasm: Finally, a strategy of treatment for BRAF-mutated patients could be represented also through immunotherapy with CTLA-4 or PD-1/PDL-1 inhibitors, which have shown high activity in tumours with a high mutational burden [69,70]: BRAF mutations are often observed in smokers, whose tumours generally express a high mutational load.